| Generation of embryonic stem cells and transgenic mice expressing green fluorescence protein in midbrain dopaminergic neurons S Zhao, S Maxwell, A Jimenez‐Beristain, J Vives, E Kuehner, J Zhao, ... European Journal of Neuroscience 19 (5), 1133-1140, 2004 | 215 | 2004 |
| Final results of a phase I–II trial using ex vivo expanded autologous mesenchymal stromal cells for the treatment of osteoarthritis of the knee confirming safety and suggesting … R Soler, L Orozco, A Munar, M Huguet, R López, J Vives, R Coll, ... The Knee 23 (4), 647-654, 2016 | 181 | 2016 |
| Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled … S Albu, H Kumru, R Coll, J Vives, M Vallés, J Benito-Penalva, L Rodríguez, ... Cytotherapy 23 (2), 146-156, 2021 | 67 | 2021 |
| Use of a chronic model of articular cartilage and meniscal injury for the assessment of long-term effects after autologous mesenchymal stromal cell treatment in sheep M Caminal, C Fonseca, D Peris, X Moll, RM Rabanal, J Barrachina, ... New biotechnology 31 (5), 492-498, 2014 | 67 | 2014 |
| Metabolic engineering of apoptosis in cultured animal cells: implications for the biotechnology industry J Vives, S Juanola, JJ Cairó, F Gňdia Metabolic engineering 5 (2), 124-132, 2003 | 61 | 2003 |
| HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: a two-site study M Grau-Vorster, A Laitinen, J Nystedt, J Vives Stem cell research & therapy 10, 1-8, 2019 | 55 | 2019 |
| Evaluation of a cell-banking strategy for the production of clinical grade mesenchymal stromal cells from Wharton's jelly I Oliver-Vila, MI Coca, M Grau-Vorster, N Pujals-Fonts, M Caminal, ... Cytotherapy 18 (1), 25-35, 2016 | 54 | 2016 |
| Design and validation of a consistent and reproducible manufacture process for the production of clinical-grade bone marrow–derived multipotent mesenchymal stromal cells M Codinach, M Blanco, I Ortega, M Lloret, L Reales, MI Coca, S Torrents, ... Cytotherapy 18 (9), 1197-1208, 2016 | 50 | 2016 |
| Cartilage resurfacing potential of PLGA scaffolds loaded with autologous cells from cartilage, fat, and bone marrow in an ovine model of osteochondral focal defect M Caminal, D Peris, C Fonseca, J Barrachina, D Codina, RM Rabanal, ... Cytotechnology 68, 907-919, 2016 | 50 | 2016 |
| Mesenchymal stem cells for cardiac repair: are the actors ready for the clinical scenario? S Roura, C Gálvez-Montón, C Mirabel, J Vives, A Bayes-Genis Stem Cell Research & Therapy 8 (1), 238, 2017 | 49 | 2017 |
| Rmst is a novel marker for the mouse ventral mesencephalic floor plate and the anterior dorsal midline cells CW Uhde, J Vives, I Jaeger, M Li PLoS One 5 (1), e8641, 2010 | 47 | 2010 |
| Quality compliance in the shift from cell transplantation to cell therapy in non-pharma environments J Vives, I Oliver-Vila, A Pla Cytotherapy 17 (8), 1009-1014, 2015 | 46 | 2015 |
| Treatment of femoral head osteonecrosis with advanced cell therapy in sheep R Vélez, A Hernández-Fernández, M Caminal, J Vives, F Soldado, ... Archives of Orthopaedic and Trauma Surgery, 1-8, 2012 | 43 | 2012 |
| The challenge of developing human 3D organoids into medicines J Vives, L Batlle-Morera Stem cell research & therapy 11 (1), 72, 2020 | 41 | 2020 |
| The protection of hybridoma cells from apoptosis by caspase inhibition allows culture recovery when exposed to non-inducing conditions A Tintó, C Gabernet, J Vives, E Prats, JJ Cairó, L Cornudella, F Gňdia Journal of biotechnology 95 (3), 205-214, 2002 | 40 | 2002 |
| Protective Effect of Viral Homologues of bcl‐2 on Hybridoma Cells under Apoptosis‐Inducing Conditions J Vives, S Juanola, JJ Cairó, E Prats, L Cornudella, F Gňdia Biotechnology progress 19 (1), 84-89, 2003 | 37 | 2003 |
| First-in-human PeriCord cardiac bioimplant: Scalability and GMP manufacturing of an allogeneic engineered tissue graft C Prat-Vidal, L Rodriguez-Gomez, M Aylagas, N Nieto-Nicolau, ... EBioMedicine 54, 2020 | 32 | 2020 |
| Non-immortalized human neural stem (NS) cells as a scalable platform for cellular assays L Hook, J Vives, N Fulton, M Leveridge, S Lingard, MD Bootman, A Falk, ... Neurochemistry international 59 (3), 432-444, 2011 | 31 | 2011 |
| Randomized clinical trial: expanded autologous bone marrow mesenchymal cells combined with allogeneic bone tissue, compared with autologous iliac crest graft in lumbar fusion … AG de Frutos, P González-Tartičre, RC Bonet, MTU Garcés, ... The Spine Journal 20 (12), 1899-1910, 2020 | 28 | 2020 |
| Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells I Oliver-Vila, C Ramírez-Moncayo, M Grau-Vorster, S Marín-Gallén, ... Cytotechnology 70, 31-44, 2018 | 28 | 2018 |
Marta CaminalVerified email at bst.cat
